Get 50% OFF This Monsoon!
Syncom Formulations (India)
No Data Available
Investor Sentiment
Syncom Formulations (India) Share price and Fundamental Analysis
Key Metrics
Included In
Stock Returns
Stock Heatmap
No Stocks
Smart Score
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
Technicals
Returns Calculator
If you would have investedResearch Report
No Research Report
Corporate Action
Financials
Key Ratios
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
Dividend History
5 Year FactSheet
Documents
No Data Available
News
Syncom Formulations (India) Management and History
Company Management
Unlock Management Data
See Detailed Analysis & Insights
Company History
Incorporated as a private limited company in 1988, Syncom Formulations (India) Limited was converted into a public limited company in Jun.'92. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh.
Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.
The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda.
In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis.
In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995.
During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.
During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%.
During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.
The modernisation of injectable section by putting Tunnel System and other modern equipments and expansion of tablet department by putting high speed mega press machines was completed in 2002. The Company carried out an expansion program of the installed capacities of its manufacturing unit at Pithampur, Dist. Dhar to increase the capacity of tablet section by 35% and also doubling of the capacity of capsule section. Capacity of packing section was increased in line with the increase in capacity of the said formulation sections. The expansion cum modernization program was implemented at a total cost of Rs. 1.34 crore out of which the major expenditure was incurred in 2002-03. The expanded capacities were made available for production from May, 2003.
In 2007, the Company launched a new division 'Cratus Life Care' to expand its operations. The expansion cum modernization project at Pithampur unit was completed with the total investment costing Rs 15.17 Crore during the year 2007-08. The Company raised long term financial resources by way of preference issuance of 3,10,000 equity shares of Rs.10 each at a premium of Rs.36 per share on 29 March, 2008 to the promoters of the Company and the said Equity got listed with the BSE in 2008.
In 2020-21, the business activity of the Company was expanded by increasing the overall production capacity of Injectable capacity from 200 Lakhs to 300 Lakhs per annum and to modernize the Tablet Department within an overall cost of Rs. 4031.50 Lakhs which was funded by the issuance of fresh share capital to meet the overall cost of the project.
Syncom Formulations (India) Share Price
Syncom Formulations (India) share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Syncom Formulations (India) Market Cap
Market capitalization of Syncom Formulations (India) indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Syncom Formulations (India) is valued compared to its competitors.
Syncom Formulations (India) PE Ratio
Syncom Formulations (India) PE ratio helps investors understand what is the market value of each stock compared to Syncom Formulations (India) 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
Syncom Formulations (India) PEG Ratio
The PEG ratio of Syncom Formulations (India) evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Syncom Formulations (India) ROE (Return on Equity)
Return on Equity (ROE) measures how effectively Syncom Formulations (India) generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Syncom Formulations (India) ROCE (Return on Capital Employed)
Return on Capital Employed (ROCE) evaluates the profitability of Syncom Formulations (India) in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Syncom Formulations (India) Total Debt
Total debt of Syncom Formulations (India) shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
Syncom Formulations (India) Debt to Equity Ratio
The Debt-to-Equity (DE) ratio of Syncom Formulations (India) compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
Syncom Formulations (India) CAGR (Compound Annual Growth Rate)
CAGR shows the consistent growth rate of Syncom Formulations (India) over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Syncom Formulations (India) Technical Analysis
Technical analysis of Syncom Formulations (India) helps investors get an insight into when they can enter or exit the stock. Key components of Syncom Formulations (India) Technical Analysis include:
Support Levels (S1, S2, S3)
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
Resistance Levels (R1, R2, R3)
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Syncom Formulations (India) shares often struggle to rise above due to selling pressure.
Syncom Formulations (India) Dividends
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Syncom Formulations (India) ’s financial health and profitability.
Syncom Formulations (India) Bonus Shares
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Syncom Formulations (India) Stock Split
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
Syncom Formulations (India) Financials
The financials of Syncom Formulations (India) provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
Syncom Formulations (India) Profit and Loss Statements
The profit and loss statement of Syncom Formulations (India) highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Syncom Formulations (India) .
Syncom Formulations (India) Balance Sheet
The balance sheet presents a snapshot of Syncom Formulations (India) ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Syncom Formulations (India) Cashflow Statements
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
SEBI REGISTERED RESEARCH ANALYST REGISTRATION NUMBER: INH000015729Disclaimer: "Investments in securities are subject to market risks. Read all the related documents carefully before investing." Receiving registration from SEBI and certification from NISM does not assure the performance of the intermediary or guarantee returns to investors in any manner. Compliance Email: [email protected]
Features
Portfolio Analysis
Screener
Stock compare
Buckets
Watchlist
Superstar Portfolio
Market
List of BSE200 Companies
List of NIFTY500 Companies
List of NIFTY NEXT 50 Companies
NIFTY Top gainers in 5 Days
NIFTY100 Most Active Stocks
NIFTY Top Gainers in 1 Month